OPKO Health, Inc. (OPK) Current Ratio
- Current ratio · latest quarter: Value 3.35×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 3.35× | Current assets / current liabilities. $500.24M ÷ $149.37M ≈ 3.35× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 500.24M USD | Assets, Current |
| Current obligations | 149.37M USD | Liabilities, Current |
| Cash and equivalents | 300.76M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | Marketable Securities, Current · Available-for-sale Securities, Current |
| Customer receivables | 81.89M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 61.85M USD | Inventory, Net |
| Payables | 50.04M USD | Accounts Payable, Current |
| Borrowing debt due within one year | 912.00K USD | Long-term Debt, Current Maturities |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $500.24M | $149.37M | $300.76M | (m) | $81.89M | $61.85M | $50.04M | $912.00K | 3.35× |
| 2026-03-31 | $535.36M | $148.38M | $331.86M | (m) | $79.64M | $64.40M | $44.18M | $1.53M | 3.61× |
| 2025-12-31 | $581.88M | $146.68M | $364.41M | (m) | $90.25M | $65.82M | $41.10M | $1.74M | 3.97× |
| 2025-09-30 | $627.13M | $169.32M | $411.97M | (m) | $94.58M | $64.95M | $50.83M | $1.46M | 3.70× |
| 2025-06-30 | $583.33M | $171.18M | $267.28M | (m) | $99.38M | $66.34M | $56.68M | $1.52M | 3.41× |
| 2025-03-31 | $737.60M | $295.85M | $428.83M | (m) | $96.15M | $64.00M | $59.37M | $1.43M | 2.49× |
| 2024-12-31 | $662.09M | $193.10M | $426.58M | (m) | $118.02M | $56.80M | $47.07M | $437.20M | 3.43× |
| 2024-09-30 | $629.64M | $211.66M | $400.08M | (m) | $106.58M | $59.41M | $62.72M | $1.51M | 2.97× |
| 2024-06-30 | $357.98M | $219.55M | $40.58M | (m) | $105.31M | $60.15M | $82.24M | $1.60M | 1.63× |
| 2024-03-31 | $391.30M | $204.34M | $75.64M | (m) | $111.37M | $59.37M | $71.16M | $1.82M | 1.91× |
| 2023-12-31 | $309.48M | $200.05M | $95.88M | (m) | $123.38M | $65.70M | $69.68M | $1.99M | 1.55× |
| 2023-09-30 | $357.24M | $200.55M | $138.62M | (m) | $117.45M | $68.96M | $66.80M | $1.77M | 1.78× |
| 2023-06-30 | $433.79M | $226.45M | $108.11M | (m) | $210.98M | $73.75M | $87.88M | $2.66M | 1.92× |
| 2023-03-31 | $406.42M | $222.42M | $110.83M | (m) | $121.49M | $75.41M | $80.50M | (m) | 1.83× |
| 2022-12-31 | $394.52M | $213.48M | $153.19M | (m) | $127.31M | $74.06M | $66.99M | $1.72M | 1.85× |
| 2022-09-30 | $413.97M | $267.27M | $180.84M | (m) | $123.19M | $71.43M | $49.75M | (m) | 1.55× |
| 2022-06-30 | $494.75M | $215.47M | $210.46M | (m) | $158.43M | $83.31M | $56.11M | (m) | 2.30× |
| 2022-03-31 | $754.07M | $309.17M | $102.28M | (m) | $212.75M | $99.41M | $94.24M | (m) | 2.44× |
| 2021-12-31 | $823.01M | $330.01M | $134.71M | (m) | $259.64M | $86.50M | $82.04M | (m) | 2.49× |
| 2021-09-30 | $557.51M | $283.04M | $148.60M | (m) | $255.19M | $112.86M | $94.39M | (m) | 1.97× |
| 2021-06-30 | $547.03M | $303.98M | $65.76M | (m) | $265.86M | $134.72M | $88.51M | (m) | 1.80× |
| 2021-03-31 | $599.05M | $403.93M | $89.50M | (m) | $320.46M | $159.10M | $162.69M | (m) | 1.48× |
| 2020-12-31 | $523.18M | $375.48M | $72.21M | (m) | $286.31M | $132.34M | $100.88M | (m) | 1.39× |
| 2020-09-30 | $428.11M | $335.89M | $36.29M | (m) | $241.54M | $111.87M | $65.69M | (m) | 1.27× |
| 2020-06-30 | $360.05M | $279.54M | $21.61M | (m) | $214.35M | $72.97M | $44.67M | (m) | 1.29× |
| 2020-03-31 | $274.46M | $245.09M | $34.53M | (m) | $132.48M | $58.70M | $55.87M | (m) | 1.12× |
| 2019-12-31 | $324.05M | $249.12M | $85.45M | (m) | $134.62M | $53.43M | $62.54M | (m) | 1.30× |
| 2019-09-30 | $292.84M | $270.14M | $64.67M | (m) | $140.76M | $50.11M | $77.30M | (m) | 1.08× |
| 2019-06-30 | $344.23M | $283.37M | $111.11M | (m) | $148.29M | $48.29M | $60.38M | (m) | 1.21× |
| 2019-03-31 | $435.24M | $396.06M | $207.25M | (m) | $144.38M | $44.61M | $51.09M | (m) | 1.10× |
| 2018-12-31 | $317.73M | $288.32M | $96.47M | (m) | $143.91M | $42.30M | $47.40M | (m) | 1.10× |
| 2018-09-30 | $289.82M | $317.83M | $43.72M | (m) | $157.37M | $43.38M | $65.61M | (m) | 0.91× |
| 2018-06-30 | $321.56M | $306.86M | $80.38M | (m) | $152.78M | $46.75M | $69.06M | (m) | 1.05× |
| 2018-03-31 | $349.35M | $318.08M | $99.94M | (m) | $158.64M | $49.81M | $64.23M | (m) | 1.10× |
| 2017-12-31 | $348.86M | $312.03M | $91.50M | (m) | $165.52M | $49.33M | $74.31M | $11.93M | 1.12× |
| 2017-09-30 | $430.56M | $258.95M | $100.36M | (m) | $233.92M | $46.95M | $66.54M | $16.11M | 1.66× |
| 2017-06-30 | $472.52M | $283.05M | $130.53M | (m) | $251.75M | $48.29M | $62.15M | $14.50M | 1.67× |
| 2017-03-31 | $459.93M | $264.95M | $131.05M | (m) | $238.89M | $47.49M | $74.56M | $11.53M | 1.74× |
| 2016-12-31 | $483.60M | $240.02M | $168.73M | (m) | $220.28M | $47.23M | $53.36M | $11.98M | 2.01× |
| 2016-09-30 | $502.07M | $254.51M | $144.65M | (m) | $223.83M | $43.19M | $58.54M | $9.89M | 1.97× |
| 2016-06-30 | $505.57M | $281.24M | $156.01M | $15.63M | $213.37M | $42.05M | $61.06M | $10.33M | 1.80× |
| 2016-03-31 | $453.53M | $267.23M | $174.97M | (m) | $204.48M | $40.58M | $73.44M | $11.45M | 1.70× |
| 2015-12-31 | $454.06M | $251.90M | $193.60M | (m) | $193.88M | $39.68M | $72.53M | $11.47M | 1.80× |
| 2015-09-30 | $517.42M | $357.59M | $212.14M | (m) | $189.72M | $40.69M | $77.97M | $78.51M | 1.45× |
| 2015-06-30 | $278.34M | $180.48M | $221.22M | (m) | $26.98M | $20.52M | $16.04M | $14.60M | 1.54× |
| 2015-03-31 | $394.02M | $182.84M | $348.19M | (m) | $19.06M | $18.32M | $10.47M | $13.60M | 2.16× |
| 2014-12-31 | $142.87M | $83.11M | $96.91M | (m) | $19.97M | $16.60M | $8.74M | $13.46M | 1.72× |
| 2014-09-30 | $163.15M | $76.84M | $118.26M | (m) | $21.21M | $16.66M | $8.84M | $12.45M | 2.12× |
| 2014-06-30 | $183.01M | $79.40M | $134.01M | (m) | $23.11M | $18.33M | $10.04M | $14.40M | 2.30× |
| 2014-03-31 | $205.27M | $84.50M | $156.40M | (m) | $19.66M | $18.86M | $14.70M | $11.03M | 2.43× |
| 2013-12-31 | $242.73M | $91.85M | $185.80M | (m) | $19.77M | $18.08M | $13.41M | $12.56M | 2.64× |
| 2013-09-30 | $241.28M | $71.38M | $155.83M | $25.00M | $21.37M | $19.52M | $13.63M | $14.48M | 3.38× |
| 2013-06-30 | $230.12M | $59.47M | $119.06M | $50.03M | $22.23M | $19.78M | $11.65M | $16.78M | 3.87× |
| 2013-03-31 | $237.68M | $58.22M | $181.60M | $28.55M | $21.17M | $23.02M | $11.29M | $20.26M | 4.08× |
| 2012-12-31 | $78.66M | $52.38M | $27.36M | (m) | $21.16M | $22.26M | $10.20M | $17.53M | 1.50× |
| 2012-09-30 | $87.98M | $46.44M | $23.43M | $18.92M | $19.14M | $21.49M | $7.24M | (m) | 1.89× |
| 2012-06-30 | $92.35M | $31.71M | $38.17M | $17.12M | $15.90M | $17.09M | $4.40M | (m) | 2.91× |
| 2012-03-31 | $99.41M | $29.70M | $47.12M | $15.00M | $16.25M | $18.39M | $4.88M | $14.19M | 3.35× |
| 2011-12-31 | $99.58M | $18.78M | $71.52M | (m) | $12.54M | $13.34M | $4.89M | (m) | 5.30× |
| 2011-09-30 | $117.63M | $20.24M | $47.23M | $40.18M | $12.69M | $10.52M | $2.56M | (m) | 5.81× |
| 2011-06-30 | $127.63M | $21.53M | $38.85M | $55.00M | $15.53M | $16.33M | $2.89M | (m) | 5.93× |
| 2010-12-31 | $57.39M | $27.60M | $18.02M | (m) | $11.86M | $16.42M | $6.48M | $14.69M | 2.08× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |